Cardax

39 articles about Cardax

• Cardax Refocuses on ZanthoSyn® Consumer Health Business

  8/31/2021

  Cardax, Inc., announced today that it is refocusing its business strategy on its astaxanthin dietary supplement ZanthoSyn® for consumer health.

• Cardax Voluntarily Suspends SEC Reporting Obligations

  8/11/2021

  Cardax, Inc. announced the filing of a Form 15 with the U.S. Securities and Exchange Commission to voluntarily suspend its reporting obligations under Section 15 of the Securities Exchange Act of 1934.

• Cardax Reports Q1 2021 Results

  5/14/2021

  Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312 in Q1 2021 primarily due to reduced salaries & wages, professional fees, stock based compensation, and selling, general, & administrative expenses.

• Cardax Reports 2020 Results

  4/15/2021

  Cardax, Inc. (OTCQB:CDXI) reported its 2020 results

• Cardax Reports Q3 2020 Results

  11/13/2020

  Financial Results. Operating loss decreased from $1,191,711 in Q3 2019 to $705,760 in Q3 2020, primarily due to a decrease in professional fees, research & development, salaries & wages, and selling, general, & administrative expenses.

• Cardax Reports Q1 2020 Results

  5/15/2020

  Financial Results. Net losses from the same quarter last year decreased 11.7%, from $1,135,420 in Q1 2019 to $1,002,868 in Q1 2020, primarily attributed to a decrease in selling, general, and administration expenses.

• Cardax Reports 2019 Annual Results

  3/30/2020

  CHASE Clinical Trial. On September 23, 2019, the Company announced findings from the pre-specified interim review of its ongoing CHASE clinical trial.

• Cardax Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease

  3/20/2020

  Cardax seeking strategic collaborations to further develop astaxanthin for COVID-19 (OTCQB:CDXI) today released a white paper outlining the potential role of astaxanthin in the treatment of coronavirus disease and is seeking strategic collaborations to further develop astaxanthin for COVID-19. The

• Cardax, Inc. Announces Reverse Stock Split of Common Stock

  1/14/2020

  Cardax expects that upon the opening of trading on January 15, 2020, its common stock will trade on the OTCQB on a split-adjusted basis under the current symbol "CDXI" and the new CUSIP number 14141D201.

• Cardax Reports Q3 2019 Results

  11/14/2019

  Cardax, Inc. (OTCQB:CDXI) announced results for the third quarter of 2019.

• Cardax Announces Interim Results from CHASE Clinical Trial

  9/23/2019

  Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its ongoing CHASE (Cardiovascular Health Astaxanthin Supplement Evaluation) clinical trial.

• Cardax Reports Q2 2019 Results

  8/14/2019

  Cardax, Inc. filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.

• Cardax Files Registration Statement for Proposed $15 Million Follow-On Offering

  8/14/2019

  Cardax, Inc. announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed follow-on public offering of up to $15 million of the Company's common stock and warrants.

• Cardax Reports Q1 2019 Results

  5/17/2019

  Cardax, Inc. (OTCQB:CDXI) announced results for the quarter ended March 31, 2019, in its Quarterly Report on Form 10-Q filed May 15, 2019 with the SEC.

• Cardax Reports 2018 Results

  3/28/2019

  Cardax, Inc. announced results for the year ended December 31, 2018, in its Annual Report on Form 10-K filed today with the SEC.

• Cardax to Present at NobleCon XV

  1/25/2019

  Cardax, Inc. (OTCQB: CDXI), a life sciences company focused on inflammatory health, today announced that its CEO, David G. Watumull, will present at NobleCon XV—Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida—on January 28th at 11:30 AM Eastern Standard Time.

• Cardax and GNC Announce Expanded ZanthoSyn® Sales and Marketing Program

  12/3/2018

  ZANTHOSYN® #1 AT GNC STORES IN HAWAII FOR PAST 12 MONTHS

• Cardax Names Former Amarin Head of Development Paresh N. Soni, MD, PhD, to lead Clinical and Regulatory Strategy

  11/28/2018

  Cardax, Inc. announced that Paresh N. Soni, M.D., Ph.D., the former Senior Vice President and Head of Development for Amarin Corporation, will join Cardax as Chief Clinical and Regulatory Strategist and as a member of the Company's Scientific Advisory Board.

• Cardax Reports Q3 2018 Results

  11/13/2018

  Robust ZanthoSyn® Sales Growth Continues

• Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health

  10/2/2018

  Cardax, Inc. has launched its Cardiovascular Health Astaxanthin Supplement Evaluation clinical trial targeting cardiovascular inflammatory health.